clinical trial · NCT06821503
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase2·recruiting·n = 72
Advanced Pancreatic CancerLM-108 injectionPenpulimab injectionPaclitaxel for injection (albumin bound)Gemcitabine hydrochloride for injection
brief summary
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.
started
Apr 11, 2025
primary completion
Dec 1, 2027
completion
Dec 1, 2028
last updated
Mar 10, 2026
official title
An Open Label Phase Ib/II Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab Plus Chemotherapy in Patients With Advanced Solid Tumors - Cohort C
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol